Latest Conference Coverage

Fenfluramine Shows Clinical Benefit in Dravet for Adults as Well as Children

The US Early Access Program for fenfluramine allowed access to the treatment for patients who were ineligible for clinical trials.

Long-Term Perampanel Efficacious Regardless of Enzyme-Inducing Anti-Seizure Medications

Patients receiving perampanel in combination with an enzyme-inducing anti-seizure medication may require a higher perampanel dose to achieve similar efficacy with only non-EIASMs.

William Rosenfeld, MD: Enduring Efficacy of Cenobamate

The neurologist from the Comprehensive Epilepsy Care Center for Children and Adults, in St. Louis, Missouri, discussed how patients found cenobamate effective for up to 43 months.

SUDEP Rates Greater Than Previously Reported, Higher Among Nonwhite Children

Study data from the NIH/CDC Sudden Death in the Young (SDY) Case Registry suggest that nonwhite children and infants have rates of SUDEP mortality 1.5 times higher than whites.

Personalized Neuromodulation Therapy Reduces Seizures Safely in Drug-Resistant Epilepsy

Microburst stimulation was also found to be more tolerable than standard stimulation in patients with drug-resistant epilepsy.

Eric Segal, MD: Diazepam Clinical Utility Regardless of Concomitant Benzodiazepines

NeuroVoices: Christian Meisel, MD, PhD, on Forecasting Seizures

Christian Meisel, MD, PhD, department of neurology, Universitätsmedizin Berlin, and Berlin Institute of Health, discussed the landscape for devices that forecast seizures, including the use of multi-modal wristband sensors.

Pediatric Epilepsy Laser Ablation Shows Efficacy With Few Complications

The registry is planning to expand, with 5 additional centers recently agreeing to participate and institutional research ethics applications underway.

Cannabidiol Effective in TSC Regardless of Infantile Spasm History

Effect modification analysis showed that the treatment effect when using CBD was comparable between patients with and without infantile spasm history.

Vineet Punia, MD, MS: Initial Data from ELEVATE Trial of Perampanel for Focal Onset Seizures

The neurologist from Cleveland Clinic discussed the potential of using perampanel as a monotherapy for patients with focal onset seizures.

Intermittent Midazolam Administration Yields Return to Functionality for Seizure Cluster Episodes

Data from this post-hoc analysis show slight differences between repeated administration of 1 and 2 doses of midazolam.

Fenfluramine Shows Potential in CDKL5 Deficiency Disorder

No patient with CDKL5 Deficiency Disorder developed valvular heart disease or pulmonary arterial hypertension while being treated with fenfluramine.

Brivaracetam May Improve Quality of Life for Patients With Focal Seizures

Interim data from a real-world study suggest that adjunctive treatment with brivaracetam is well-tolerated and may improve quality of life over 12 months for those with focal seizures.

Both Low- and High-Dose Perampanel Effective and Well-Tolerated

The data suggest that some patients with partial-onset seizures may benefit from lower doses to mitigate treatment emergent adverse events, but these must be tailored to each patient.

Kelly Knupp, MD: Fenfluramine in Lennox-Gastaut Syndrome

The pediatric neurologist and epilepsy specialist at Children’s Hospital Colorado detailed the results of study of fenfluramine in patients with Lennox-Gastaut syndrome.

Diazepam Effective Regardless of Antiseizure Medication Use

The safety profile of diazepam remained similar to what was previously observed, but generally, more patients in the concomitant benzodiazepine subgroup experienced more TEAEs.

William Rosenfeld, MD: Continuing Studies on Cenobamate

The neurologist from the Comprehensive Epilepsy Care Center for Children and Adults, in St. Louis, Missouri, discussed how high rates of seizure reduction were seen in treating drug resistant epilepsy.

Real World Experience Study of Brivaracetam for Focal Seizures Announced

Top line results from the retrospective EXPERIENCE study of brivaracetam are expected to read out in early 2021.

Cannabidiol Efficacy Confirmed in Lennox-Gastaut Syndrome

The GW Pharmaceuticals product has shown confirmed efficacy in LGS, though the study failed to produce a firm conclusion regarding its efficacy in other drug-resistant epilepsies.

Eric Segal, MD: Effects of Diazepam Amid Concomitant Benzodiazepine Use

The director of pediatric epilepsy at the Northeast Regional Epilepsy Group discussed his study presented at AES 2020 which involved the effectiveness of diazepam nasal spray regardless of treatment regimen.

Multi-Modal Wristband Sensors May Predict Seizures

The initial study results may provide the basis for future evaluation as a step towards patient empowerment and objective epilepsy diagnostics for broad application.

Vineet Punia, MD, MS: Phase 4 ELEVATE Trial of Perampanel for Partial Onset Seizures

The neurologist from Cleveland Clinic discussed initial data from Study 410 and patient compliance rates with perampanel treatment.

Christian Meisel, MD, PhD: Forecasting Seizures Using Multi-Modal Wristband Sensors

The neurologist from Universitätsmedizin Berlin and Berlin Institute of Health detailed his study from AES 2020 on using wristband sensor data to forecast seizures.

Reduction in Concomitant Antiseizure Medications Improves Cenobamate Retention Rates

High retention rates and number of patients remaining seizure-free for prolonged periods indicated the efficacy of cenobamate in treating focal seizures.

Fenfluramine Demonstrates Efficacy in Lennox-Gastaut Syndrome in Phase 3 Results

Fenfluramine was particularly effective in reducing generalized tonic-clonic seizure frequency in patients with Lennox-Gastaut syndrome, with a push for regulatory submission in the future.

Perampanel Reports High Compliance and Good Tolerance in Phase 4

High compliance rates and well-tolerance of perampanel indicate its efficacy as a treatment for partial onset seizures.

Benjamin M. Segal, MD: Escalation Versus Induction in MS

The chair of the department of neurology at The Ohio State University spoke to the ongoing conversation in MS about how aggressive to be with treatment early on.

Impact of Results From the COVID-19 in MS Global Data-Sharing Initiative

COVID-19 in MS Global Data-Sharing Initiative Anti-CD20 Therapy Results

CLARITY Extension Trial: Disability Improvement With Cladribine